For research and educational purposes only. Not medical advice.
Sermorelin Reference
Educational, not medical advice reference for Sermorelin: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also known as G…
Reference summary
Older US pediatric and adult studies documented growth hormone release following sermorelin administration during its approved-product era, and it was widely used for GH provocative testing. Independent modern clinical outcome data are limited compared with current approved GH-axis therapies.
- Categories
- GH Release
- Aliases
- GRF 1-29, Sermorelin acetate, Geref, Geref Diagnostic
- Evidence posture
- human — Original US label was withdrawn in 2008. Current use is via compounding and falls outside FDA oversight.
- Regulatory status
- Sermorelin acetate was FDA-approved as Geref (pediatric idiopathic GH deficiency) and Geref Diagnostic (GH provocative testing), and the last sermorelin product was discontinued from the US market around 2008. No FDA-approved sermorelin drug label is currently on the US market; present clinical use is via compounding pharmacies. FDA lists sermorelin among bulk drug substances with safety-risk concerns for compounding.
- Content review status
- research reference